CLINICAL_TRIALS
trial_result
· 2008-12-19
Clinical Trial Update: Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia [Phase 2]
Summary
A Phase 2 dose-ranging trial of AVE1625 in abdominally obese patients with atherogenic dyslipidemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Obesity, Dyslipidemia | Phase 2 | Status: COMPLETED